focus -WSS

focus

author：explore 2025-08-29 19:54:13 - browse：48

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Melinda French Gates resigns from Gates Foundation

WSS

MassMutual is introducing free genetic testing for members

MassMutual is introducing free genetic testing for members

Patients' immediate access to test results puts radiologists in a bind

AI models in health care face new federal disclosure requirements

More tobacco lobbyists active in statehouses

After sickle

knowledge

focus

focus

Apple is now the first public company to be valued at $3 trillion

STAT letters to the editor on burnt

Continuity nursing helped my family in our darkest PICU moments

AI models in health care face new federal disclosure requirements

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why rehabilitation engineers need to center patients in their research

BioMarin wins approval for gene therapy to treat hemophilia A

Chemotherapy shortages won’t get better under Biden’s latest plan

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Chemotherapy shortages won’t get better under Biden’s latest plan

focus

Bird flu outbreak in cows is latest avian flu curveball

More tobacco lobbyists active in statehouses

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Close Medicare's dangerous gaps in addiction treatment coverage

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Cancer researcher Catriona Jamieson is sending tumors into space

entertainment

leisure time

hotspot

hotspot